Thanks for downloading and welcome to Take Orally, the emergency medicine podcast recorded at Dream Queen's Medical Centre at Nottingham. In this episode we'll be discussing community-acquired pneumonia. As ever, all information is correct at the time of recording. All information is correct for Nottingham University Hospital's NHS Trust. Other trust guidelines may vary. All views and opinions are the speaker's own.
Hello, welcome back to Take Aurely. Jamie Thomas, teaching fellow in emergency medicine here. You can find me on Twitter at McDreamy. And once again, joined by my favourite respiratory physician, Dr. Harry Pick, reg in respiratory medicine, and also a research fellow. Welcome back, Harry. Hi, thanks, Jamie. Are you on Twitter? I'm not, no. I can't get up with that. You're not on social media? No, I'm not, no. Although we have just launched a pneumonia trust website as a group, research group. It's www.pneumoniatrust.co.uk. So that's a resource for patients, healthcare professionals.
telling them a little bit about pneumonia, patient experiences of pneumonia. Some of the national guidelines are linked on there, but also research we're doing in the area of national. So that's www.pneumoniatrust.co.uk. Have a look. We'll do, okay. Eddie will be very pleased that you do. Okay, so a vision into how Harry met Jamie, which is the sequel to the film that nobody ever wants to see. We met when you presented at our academic meeting about community-acquired pneumonia. Yes, that's right. Or CAP. We'll be using both phrases here. And so that's how we got talking and how these podcasts we've done have come about. So this podcast, we're going to be looking at community-acquired pneumonia or CAP. Yes. Certainly something I see very commonly and will diagnose very commonly in A&E and sort of the bread and butter of a respiratory physician. Yeah, yeah, it's a very common diagnosis.
for all of us, actually. So I think the first thing to really define what is community-acquired pneumonia. So the BTS definition is a patient presenting with signs and symptoms consistent with an acute lower respiratory tract infection, so shortness of breath, productive cough, febrile, myalgia, arthralgia, and chest pain again, pleuristic chest pain, in association with when they're in hospital or attending hospital, new radiographic changes on their plain chest x-ray, and that the illness is the main reason that they've come to hospital. Okay. the pneumonia or its associated signs of symptoms and that the admitting clinician treats the patient as the pneumonia as well. Okay. So that's interesting. That's part of the definition is that you treat it as something. Yeah, yeah. And the other thing is that you still have developed within the community or within 48 hours of being admitted to hospital. Yes, because otherwise you're into the realm of hospital-acquired pneumonia, aren't you? It's a bane of my life for I differentiate the two. Yes. And one of the things that's become quite clear in more recent guidelines is the...
move away from using phrases such as atypical pneumonia. So there isn't really anything such as atypical pneumonia itself. Pneumonia is a constellation, a clinical diagnosis, an umbrella term, of which community-acquired pneumonia is one of those. Something we would like to encourage the use of is pneumonia is second due to atypical pathogens. So most people, when they're talking about atypical pneumonia, is actually that it's due to a funny bug rather than a funny presentation with pneumonia. Exactly. So atypical pneumonia is not what we want. It's community-acquired pneumonia. And if you think it might be due to one of those atypical bugs, you can say atypical pathogen. It just helps us to really clear the waters. Because I mean, half the problem with lower respiratory tract...
infections, acute bronchitis, chest infections, pneumonia is the labelling, the diagnosis, how people are allocated to which of those groups. And it does have effects on what patients expect, but also how they're treated. So trying to get that accuracy in there is really important. Sure. So do you have any raw data then about the scale of this problem? We know you like a good statistic. As you probably found from the PE podcast, I'm keen on my numbers. So the incidence of CAP diagnosed in the community is currently between 5 and 11 cases per 1,000 of the population. The community-acquired pneumonia represents about 10% of lower respiratory tract infections presenting in the community. And of those patients in the community, between 20 and 40% will eventually require admission to hospital for CAP.
So it's not an insignificant problem. The incidence of cat presenting to hospital is between 1.4 and 1.98 per thousand population. That's been increasing over recent years. Disproportionately affects the elderly as well. So in the young, that level is around the 1 per thousand population. It's more like 13 to 15 per thousand population for the elderly. And in the UK, so England and Wales, there's over 100,000 hospital admissions per year for community-acquired pneumonia.
Interestingly, mortality with CAP in the community is around 1%. So if you get pneumonia diagnosed by a GP, able to stay out of hospital, managed in the community, risk of mortality is about 1%. If you're hospitalised with any severity, it's between 5% and 14% mortality. If you end up in critical care with pneumonia, mortality is over 30%. And the 5-year CAP mortality is 40%, which was a surprising stat for me, actually. So of those patients you see in ED, 4 out of 10 of them.
would have died within five years. And that's no reflection on my qualities as a clinician, I hope. Having never seen any of these, I wouldn't possibly want to comment. Do you think that's because of comorbidities as well? If you said they're more common in the elderly population. Yeah, I don't know whether it's been proven that it's a reflection of CAP itself as a diagnosis or the fact that pneumonia is more common in the elderly, multi-morbid population and it is a marker of disease severity and chicken and egg a little bit, isn't it? Is it the COPD? Is it the CAP? Yeah. But it's interesting to think, I think currently there is a bit of a perception around community-acquired pneumonia that it is common.
benign, but also that it's relatively easy to manage and investigate and manage properly. And I think some of the evidence we have from the national audit, some of the evidence from outcomes shows that there's room for improvement in that across all sectors going, the front door service, acute medicine, respiratory medicine, general medics, treating new medics, we all see it, and there's plenty of room for improvement within there. Okay. So what causes can you to acquire new medics? What bugs are? Very interesting. So no study of incidence or etiology for new medics will ever be the same. And that's a lot to do with country it's conducted in, system it's conducted in, type of research.
hospital overwhelming majority of bacterial pathogens of which streptococcus pneumoniae is the commonest cause in all ages and is responsible for around about half of all pneumonia infections so very common most common in winter so this time of year we're starting to ramp up to our pneumococcal pneumonia season and there's over 92 serotypes of streptococcus pneumoniae 23 of them are responsible for 90% of those 50% of infections as you probably know there's a pneumococcal vaccine given to children. So the evidence behind that came from the US and was then confirmed and it's been brought to the UK population. So that's a vaccination against 13 of the serotypes, the commonest causes of infection in children for pneumococcal disease. And there's been a significant reduction in invasive pneumococcal bacteremia in children, but also a reduction in the rate of pneumococcal infection in adults as a consequence of herd immunity. There's also the pneumococcal vaccine for adults over the age of 65, covers for 23 of the serotypes.
The evidence for reducing or preventing pneumonia is less clear in that population. It would suggest that it reduces the severity of the pneumonia you get if you get it, but it doesn't stop you from getting pneumonia. And other pathogens that are implicated are Haemophilus influenzae, Moraxelia cataris. and serratia in bacterial and then there's the atypical pathogens we just alluded to so legionella mycoplasma chlamydia and coxiella and so legionella typically textbook associated with your holiday to benador air conditioning units it's often a pathogen we see more frequently in summer and autumn months usually travel related but also outbreaks related to war spawn infection and then there's also mycoplasma It tends to occur in epidemics, affects the young adults, middle age, more than elderly. Epidemics have been three to four years and winter predominance. And then coxiella burnetta, I just wanted to throw out there for a weird and wonderful diagnosis when you're in a prostate ward round. Don't not mention this first, but it's associated with exposure to animals, usually sheep. Interestingly, only 8% of people who have coxiella have an occupational history working with animals, and the other 90% have exposure through other sources.
which I thought was quite interesting. And then the other causes of community-wide pneumonia are viruses. So rhinovirus, influenza, parainfluenza, and adenovirus. Recent studies using PCR rather than culture methods have shown that there's two or more bacterial species in pneumonia in about 30% of cases. And viruses are co-implicated with bacteria in about 80% of the cases. So it's interesting. So I suppose the clinical implication of that is if you've done your microbiological investigations, we'll come to talk about it shortly, but you found a bacteria that could well be a virus.
But if you find a virus and not a bacteria, the chances are there is a bacteria there, so you should carry on with the viral and antibacterial treatments, if you're thinking of it. Does that make sense? That makes sense. So I suppose you've got a new patient, you treat him with antibiotics, you do a viral 312, the virus comes back, you don't stop the antibiotics, but you can add in an antiviral treatment, if appropriate, and that's a separate issue in and of itself. So I think that's probably it on the etiology side of things. And so what guidelines are there to help us? Yeah, so the guidelines we use in terms of community-wide pneumonia, there's the British Thoracic Society community-wide pneumonia guidelines. So there's an update from those from 2009. There's the NICE pneumonia guidelines from 2014. And then there's the Infectious Disease Society of America slash ATS guidelines from 2007. And whenever we're talking about infection, there's always the surviving sepsis and sepsis-related guidelines. So there's the surviving sepsis campaign guidelines from 2016. And so they're the things we can refer to in organizing community-wide pneumonia.
And most hospitals will have a trust level guideline, and NUH certainly does. So how are we going to then manage our patients? Because like we talked about PE, they don't come in with a label. So we've got a patient come in with a productive cough, with a fever. How are we going to manage them? Yeah, so I think, as we've alluded to in previous podcasts, it's always ABCDE assessment, sort of drilled into all of this. And so you check, there's no adverse features within that assessment. And then when you're happy, you can settle down and get into the nuts and bolts of taking a history and examination. For me, I think the really important thing to do with any infection, but also community-acquired pneumonia, is having your own minds.
separating the patients out into people with infection as opposed to sepsis. And so we see it quite commonly that patients with pneumonia will be labelled as sepsis because of a scoring regime or their EWS, and they get run down a pathway which isn't necessarily the right one. And I think you need to have it in your own mind of what is sepsis and what is infection. For me, with sepsis, there's good evidence, strong evidence that the range, the battery interventions delivered within one hour has morbidity and mortality implications. So you deliver the sepsis six within an hour, you start antibiotics. There are very clear guidelines that show that helps. For every hour over that, there is clear indication that you don't do as well. I think it's a 17% reduction in your survival for every hour that you take longer than that. So for sepsis, so people hitting the sepsis signs who you think have got an acute lower respiratory tract infection, get down the sepsis side of it, plough in the fluids, get on with the antibiotics, do the investigation associated with that. At this point, I would...
point out to the take or release sepsis podcast it's already out there so have a listen to that if you want to refresh yourself about sepsis and its implications sorry Harry I'm cutting you off no it's okay so that's one category sepsis the thing for me is there is In adverse consequences of all of this, sepsis education, sepsis management, focus on sepsis, in that a lot of other conditions where they're not septic but they have an infection are managed as if they are sepsis. And that has, for me, implications on appropriate antibiotic use and treatment for patients. So in my mind, I'd like to say that people with acute lower respiratory tract infections who don't hit sepsis, the guidelines and the evidence is them getting treatment within four hours is the target. If you treat people in under four hours, they have a survival and mortality benefit. Over four hours, there is a reduction. There is no evidence in those people that treating them within one hour versus four hours increases their output.
they're chance of a good outcome. So I think having it clear in your mind, sepsis versus infection, sepsis one hour, infection four hours. And the reason I think that's important is it gives you the opportunity to confirm the diagnosis through other investigations, to think about what antibiotics you're going to use. In the era of antibiotic stewardship, the millennial goals, the funding from the government to reduce antibiotic prescriptions, I think that's key. But also then to have some investigations to say, well, this is likely to be XYZ pathogen, let's go that way. So I suppose you've done your A2B assessment, you've figured out whether they're sepsis or they're...
regular infection you're taking your history you determine you think it's the chest that's the source the next thing really to do is clinical examination we know what we'd find there but then also moving on to investigations and the bts outlines what investigation should be done for people suspected community acquired pneumonia i suggest that they're probably the same investigations for someone that's got acute lower respiratory tract infection whether you're thinking exacerbation of copd acute bronchitis community acquired pneumonia this is the battery of things that they should all have so that's a set of observations and that should include assessment of their arterial oxygenation status whether that's their sats or whether that's an arterial blood cast depends a little bit on local policies My personal opinion is if they have a saturation of less than 94% in somebody with alcohol and disease, or they're requiring any supplemental oxygen, they should always have an arterial blood gas. My personal preference as a respiratory physician is anybody who comes through the door with COPD should have a baseline arterial blood gas because it helps you in their management moving forward. They should all have a chest x-ray requested. They should all have a set of bloods, FPC, UE, CRP and LFTs. They are for...
helping with diagnosis, but also risk stratification, but then also helping us manage them further down the road. Now I know CRP isn't always the favourite investigation of all trusts, cost implications, but also clinical headaches sometimes with CRP. There's good evidence in community-acquired pneumonia that a CRP at admission is useful for us in terms of assessing response to treatment further down the line. So if you compare a CRP on day one with a CRP taken on day three, you should expect a 50% reduction in that CRP level if they're on the right treatment, if they're responding. And at day seven, compared to day one, there should be a 90% reduction in that CRP. So if you're at day three or day seven, you've not got those reductions, you need to start thinking, is it the right path, right bug, right diagnosis, right antibiotic, are there resistance, is there something else going on? So it helps us to know which patients have been treating appropriately or not. There isn't any evidence that the CRP level has any relationship to outcome or how you should treat them.
So I think that's the thing where the front door services maybe have a problem with CRP is it's not a great test in terms of discrimination and it doesn't particularly help the diagnosis at that moment in time although a normal CRP in somebody who you think is about LRTI would prompt you to start thinking of something else. It helps us down the road and helps the patients eventually with their management. The other investigations, micro-abolical investigations, is blood cultures times two in everybody, preferably prior to antibiotics, although not always possible, preferably from two separate sites at separate points in time. Sputum cultures for those in moderate severe disease that haven't had antibiotics within the preceding seven days, and urinary antigens for streptococcus pneumoniae, Legionella, and those in moderate severe community of quiet pneumonia.
One of the things we're pretty hot on at the moment is trying to do viral throat swabs. There's a big variation in who gets a viral throat swab and it's often clinician-based. So we would recommend that you have a viral throat swab in anyone with severe community-acquired pneumonia because viral pathogens tend to give you a more severe pneumonia if they do. But also anybody who you think might have a suspected viral etiology for any of the conditions, so bronchitis, LRTI, pneumonia. And that's something probably poorly done at the moment where there's room for improvement.
And so I suppose that's the investigation side of it. The next thing to do would be, once you've got your investigation back, to risk stratify them. Yeah, that's because I was saying, so you were talking about moderate or severe pneumonia. So I suppose that leads to our questions. So we've got our X-ray, we're very happy we can see there's pneumonia there. We're happy that it fits our picture. I plan to treat this pneumonia. How can we work out how severe our patient's pneumonia is? Yeah, so there's two validated severity risk assessments.
One is the CURB65. It's the one that we prefer here. Developed by my boss, Prof Lim. So he developed it, validated it. He taught me at med school as well. He's a professor of respiratory medicine and consultant and respiratory physician over at Nottingham. So he developed the CURB, in conjunction with the colleagues, developed the CURB65 score. Very simple, very easy to use. There's a community-based version, which is the CRB65, which you drop the urea out of. And it's validated in a community setting for severity as well. Because you've not got the used knees. Because you've got the used knees. But it's still valid for the GPs, colleagues to use for severity assessments. So you score one for each of.
C is acute confusion, U is a urea greater than 7, R is respirator greater than 30, B is a systolic blood pressure of less than 90. and slash or diastolic blood pressure less than 60. And 65 is age over 65. The observations, so the respiratory and the blood pressure is their first when they hit the unit. So it's their first observations in ED. Before they've had oxygen started, before they've had fluids going. And sometimes actually you have to go back to the ambulance history sheets to get those because they'll come in on some oxygen. And they may have set them out of NEB, you know, maybe other things going on. So you have to look back. Sure. And so depending on what they score, 0 to 1 is rated as low severity pneumonia. And the risk of death with that risk of mortality is less than 3%. A score of 2 would be classed as moderate severity. The risk of death with...
That is around 9%. And of three or above, it's high severity. And the risk of that varies between 15% and 40%. Now, the benefit of the COP65 score is threefold, really. It guides your microbiological investigations. So it tells you whether or not you should be sending things like urinary antigens, doing sputum cultures. And the reason for that is that the high severity disease, so the atypical pathogens tend to give you high severity disease. So there's a better pickup rate if you send them in those patients. That's a urea antigen.
Urinary antigen for Legionella and pneumococcal. Yes, in severe. Moderate to severe. Moderate to severe. So yeah, two to three. So that's the first, bio-microbiological investigations. The second is it risk stratifies you, and through that it then tells you whether you can be treated as an inpatient or an outpatient, based purely on their pneumonia score, the Curve 65 score. It's not based on if they've got social ability to cope at home or they've got decomposited comorbidities. And that's a little bit where this comes into its clinical judgment alongside. And the third thing is it helps you guide your antibiotics management. So based on their severity is what empirical antibiotics you should treat that patient with.
The caveat to CURB-65 is that clinical judgment always trumps it. There's several situations where CURB-65 can give you a low score where actually you've got more severe disease, and that tends to be in the young, fit, previously healthy patients, and also people with bilateral infiltrates on chest X-ray, and those who are hypoxic, because that's not taken into account. So they're the three sort of groups where you need to just have a little bit of a caveat in your mind that actually, yes, they've got a CURB score of zero, but their SATs are 92 on air. they may need to be admitted for 24, 48 hours, or yes, they're COVID-650, but they're young and they look awful, you know, end of the bed, good test. Or, you know, they've got bilateral chest X-ray changes, looks more severe than that, so it's elucidating too at the moment. Let's keep them in a short-stay area, you know, somewhere for observation overnight, see how we get on. Sure. I suppose, getting on to the treatment aspect, we want to narrow our antibiotics as quickly as we can. I know that, you know, we talk about the sepsis 6.
And, you know, so broad spectrum in those cases. But if we are suspecting a chest source, if we've got our confirmed pneumonia, trying to narrow down as quickly as we can. Yeah, that's completely right. So we'll start with the sepsis side of things. Empirical therapy for sepsis, depending on the trust, usually involves Tazacin and or other agents. It's quite interesting. In sepsis cases where you've got an undetermined source of infection, studies have shown that 50% of that will be chest sepsis, will be due to a lower-espiratory tract infection. So actually giving them a broad spectrum antibiotic like Tazacin alongside...
something for high severity disease like a macrolide probably is the best approach, unless you've got an obvious other source. We often add on macrolides to those sorts of patients that come across. And in terms of antibody treatment, from narrowing down, the reason that low severity disease is a single agent is because the most common cause of infection in that group will be something like streptococcus pneumoniae, which is very sensitive to a penicillin and antibiotic, and the risk of failure or not treating the right pathogen is very low. The reason that high severity disease is given, penicillin-based antibiotic, or beta-lactam, plus a macrolide, is it more likely to include an atypical pathogen. So for local guidelines, NUH, these are the same as the BTS guidelines. You'd accept that because Proflim wrote them both with colleagues. So for low severity, Kerb-6x-021 is oral amoxicillin or doxycycline if you're penicillin allergic. For Kerb-6x-2, which is moderate disease, it's oral amoxicillin or oral chlorophyllamycin. And if it's high severity, so Kerb-6x-3 and above, it's IV, carmoxilin, and chlorophyllamycin. And that will cover you for the majority of pathogens.
The reason we add in the macrolide to the beta-lactam for moderate and severe is that there's been studies using the BTS pneumonia data set that have shown there's a reduced mortality in moderate to severe severity cap with the addition of a macrolide. There are studies now that are starting to refute that. They're starting to say that actually there's no benefit in adding a macrolide to empiric beta-lactam therapy. I think the jury's still out of that, but the current national guidelines for us in the UK is that we give moderate to severe severity macrolide in addition to the beta-lactam. I think until we know more about the evidence, that's what we have to carry on with. Obviously, there's risks and benefits to giving macrolides.
The other thing which we sort of alluded to in the discussion about sepsis versus infection is there's good evidence from the BTS cap set that if you give your first antibiotic within four hours, it leads to a 16% reduction in your inpatient mortality compared to patients who have it after four hours. The longer the time after the four hours that the antibiotic is delayed, there's an increase in mortality. So that four-hour window is a really, really tight thing. You would hope, here we're recording in the UK, obviously, we have our four-hour targeting A&E. You would really hope touch wood. So what proportion, Jamie, do you think of the national data set shows that they don't receive their CAP antibiotics within four hours? Oh, I would say that 0%. Obviously, I'm very proud of A&E. No, tell me that. Well, it's funny you say A&E. So the national order set shows that 70% of pneumonia comes through ED. 30% goes through a direct medical admission wards. And nationally, 35% of our pneumonia patients don't receive their first antibiotic within four hours.
Now, the caveat to that is that the BTS data set includes patients from December to January from 2009, 2010, 2011, 2012, 2014. And about halfway through that period, the four-hour targets really kicked in, and the one-hour, four-hour sets has changed. And actually, the more recent years, there is a trend to giving them more within four hours. But the overall data set shows that 35% of our patients with pneumonia don't receive antibiotics from the first four hours. So it could do better. Could do better. Lots of room for improvement.
And you mentioned clarithromycin. Is there any evidence about oral versus IV on clarithromycin? Yeah, so there's supposed to be... better bioavailability with IV. So the majority of patients normally get IV clarithromycin for the first 24 to 48 hours and then switch over to oral thereafter. I mean, there's papers one way and the other with that. And I think the practice locally is IV clarithro for the high severity with IV comox when switched over. Everything less than high severity should be oral antibiotics and quality of oral violence. There's obviously other scenarios when you think about others. So if there's aspiration, you need to think about anaerobic covering for that. And obviously hospital-acquired pneumonia is a whole behemoth subject in and of itself.
Or on ventilators. We'll skate around that one. So say in A&E, one of the challenges I have is I've given my diagnosis to my patients and said, this is what is wrong with you, and I feel great. And then they turn to me and go, so how long am I going to be in hospital, doctor? How long is it going to be until I'm better? Am I going to be better? So how long can these patients expect to be in hospital for, in your experience, and what's their recovery like? Yeah, so from the BTS data across all severity classes, the average length of the day is six days. So low severity tends to be between two and four, and moderate severity get up towards a week in hospital.
And that's usually because for the low severity, well, for all patients, when you're discharging them or switching to oral antibiotics, you're looking for them to have what we call no evidence of instability. So time to clinical improvement, basically. And so we have discharge criteria. So we don't want them to be on oxygen. We want them to tell us they feel better. Not tachycardic, not tachypneic, not febrile. And their inflammatory markers will be improving. And when all those things happen, they'll get switched on to oral tablets. And then once they've been in for 24 hours after that, they'll normally be discharged.
So if you're having two or three days of IVs, you then switch on to oral rules, and then you're going home. It's normally getting on for five or six days for the moderate and high severity. For the low severity, that tends to occur much quicker, so you can help them escape. So a lot of patients will complete between seven and 14 days of antibiotics in total. And I think the expectation management is the main thing that we need to address now. A lot of patients feel that when they finish their antibiotics, they should be back to their normal self. But we know with pneumonia that's not the case. The thing I tell them often is that it's a serious infection on your major organs. The infection is treated, but your body's got to recover from that process. And actually, it takes...
around six weeks on average to get back to your normal self. We have evidence that in some people it can take up to a year and the younger people with less comorbidities will get better quicker than six weeks. There has been a number of studies looking at recovery from pneumonia and one of the largest and most comprehensive showed that at four weeks 86% of people still have a symptom. So they still have shorter breath, fatigued, have a cough. The median time for return to work is 14 days and the median time for return to their usual activities is between 21 and 22 days. So there's a significant burden of disease in recovery. So I think the main thing to say is you will get better with time.
symptoms persisting isn't necessarily a sign of ongoing infection but recovery and expect it to take a minimum of six weeks for you to get anywhere near your normal self and it can take longer than that. Wow, six weeks? Yeah, yeah. I remember that now. Yeah, yeah. I mean, we traditionally have follow-up at six weeks for patients and that was a bit of a finger in the air, let's guess, a time point to do follow-up, something that feels right, availability of clinic slots, time for the x-ray to resolve. But actually, the whole six-week follow-up visit, the agenda is the clinicians and not the patients. And actually, the majority of people will still have symptoms. They'll be improving but they'll not be back on themselves at a time point.
Yeah, so I suppose, I mean, pneumonia is interesting as a diagnosis because sometimes, I think, like you said earlier, patients just shrug their shoulders and go, okay, you're going to give me some antibiotics and I'm going to be fine. I've also given the diagnosis and I've really upset some patients because it has that stigma of being something that, you know, people with dementia, oh, it's the old person's friend, it's what finishes, or they know an elderly relative who died. It's a strange diagnosis in that. Yeah, I think one of the major problems is we don't really know what pneumonia recovery is. So there's not been a great deal of studies defining that, and we don't know what the average time is really. We have an idea.
conducting studies in recovery from pneumonia is difficult because you only have that patient presenting when they're at the worst. You don't know what their baseline is and you can't assess their baseline other than recall. And then there's all those recall bias and what is a persistent symptom and what is what they had before. So there's lots of inherent problems with research and recovery. And I think you're right that I think there's also...
My feeling is that there's a gap between what clinicians think pneumonia is and its implications and what patients think pneumonia is and its implications. Part of that is not helped by wrong labeling or wrong allocation of diagnosis. So telling a patient they've got a chest infection when they've got pneumonia or telling them they've got a respiratory tract infection when they've got a pneumonia doesn't help them. But I think patients expect, because of their illness, that there may be scarring or this may be life-threatening or they're never going to get better from it again. And I think as clinicians think it's a...
worrying diagnosis in the short term but long term patients get better from it they don't tend to have long-lasting problems there's this mismatch i think managing expectations from that can be challenging at times and that's probably one of the reasons why we have quite high re-admission rate and re-consultation rate for pneumonia is patients feel vulnerable they want support that's not always available they're not sure what to expect so they end up going back to ed gp coming back into hospital And that six weeks, will they get a follow-up chest x-ray as well? Yeah, so evidence is that two weeks after your pneumonia, half of people's chest x-rays will have resolved. At four weeks, about 60%, and at five weeks, six weeks, about 60-70% will have improved, or resolved anyway. The follow-up visit generally is resolution of pneumonia changes on x-ray. In a small proportion of patients, pneumonia might be the first sign of an underlying structural lung disease. So something like...
bronchitis or malignancy, so lung cancer. And if it's not resolving at six weeks, depending on the picture and the risk factors, we'd either proceed to a CT scan or maybe a little bit longer in another x-ray. But the pickup is low. It's around the 5% mark. Thank you very much, Harry. Lovely. So that's community-acquired pneumonia tackled. Thank you so much for coming. Thanks, everyone, for listening. Goodbye. That was the Take Orally Community-Acquired Pneumonia podcast.
Remember, you can find Take Aurelie at www.takeaurelie.com. You can also find us on Facebook and Twitter. For more information about research and education opportunities within emergency medicine, acute medicine and major trauma, be sure to find NUH Dream on both Facebook and Twitter.